Peptides:
What Actually Works, What's Marketing, and How to Run a Protocol Honestly

A peptide is a short chain of amino acids, typically 2 to 50, joined by peptide bonds. That's the chemistry. Once a chain gets longer than about 50 amino acids, biochemists tend to call it a protein. Insulin (51 amino acids) sits right at the fence and is technically both. The category is defined by size, not by function or origin.

What that means in practice:

• Peptides are not steroids. Steroids are lipid-based hormones that diffuse into cells and bind nuclear receptors. Peptides are protein-fragment signaling molecules that bind cell-surface receptors. Different chemistry, different mechanism, different regulatory category, different risk profile.
• Peptides are not "natural" by virtue of being peptides. Many are synthetic analogs of endogenous signals. Some are engineered with modifications (like the DAC linker on CJC-1295) specifically to extend their half-life beyond what the body would ever produce on its own.
• The evidence base is wildly uneven. Tesamorelin is a generation-old FDA-approved drug with phase III trial data and a black-box safety profile. BPC-157 has 35 preclinical studies and one published clinical study at the time of the 2025 systematic review ^[1]. Treating "peptides" as one category leads to importing the safety profile of one onto another.

The category exploded in popularity over the past five years because three things happened simultaneously: bodybuilding and longevity communities found ways to source research-grade peptides at low cost; telehealth and compounding pharmacies built distribution channels; and the regulatory framework moved slower than the market. The 2025 FDA guidance is the regulatory framework catching up.

The OptiPin app sorts every compound into a category, growth, cognitive, specialty, fatLoss, longevity, and the same vocabulary is used here so you can move from a hub page directly into the matching filter in the medications library. Sort by what you want to fix, not by what's trending.

Growth & Recovery (growth)

The largest peptide bucket. Two mechanism-distinct subgroups land in the same app category because they share an outcome shape: tissue repair, recovery, and lean-mass support. The app's growth filter shows both.

Healing and regenerative peptides drive direct tissue repair without acting on the GH axis:

• BPC-157, synthetic pentadecapeptide derived from a sequence in human gastric juice. Robust preclinical evidence for tendon, ligament, GI, and vascular healing across rodent models. Human evidence is genuinely sparse: a recent systematic review identified 35 preclinical studies and 1 clinical study (a retrospective intra-articular knee pain series) plus a small intravenous safety pilot showing no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers ^[2]. Banned in WADA-tested professional sport. Not FDA approved. Run if you understand you're running on preclinical extrapolation supported by clinical anecdote.
• TB-500, synthetic fragment of thymosin beta-4. Used for similar indications as BPC-157, soft tissue healing, scar reduction. Often stacked with BPC-157 ("Wolverine stack"). Same caveat: strong preclinical, weak clinical.

Growth hormone secretagogues drive GH and IGF-1 elevation through the pituitary axis. Two further sub-mechanisms: GHRH analogs (mimic the upstream hormone that triggers GH release) and GHRPs / ghrelin mimetics (act on a separate receptor to amplify GH pulses):

• CJC-1295 with DAC, long-acting GHRH analog. Half-life 5.8–8.1 days. After a single injection, mean plasma GH rises 2–10× for 6+ days and IGF-1 stays elevated up to 28 days ^[3]. Convenient (once or twice weekly) but produces relatively continuous GH elevation rather than physiologic pulses.
• CJC-1295 without DAC ("Mod-GRF 1-29"), short-acting (~30 min). Used 2–3× daily to mimic natural GH pulse pattern. More physiologic, more injections.
• Ipamorelin, selective GHRP. Releases GH without the prolactin/cortisol/ACTH bumps that older GHRPs (GHRP-6, hexarelin) cause. Half-life ~2 hours. Standard pairing with CJC-1295 (no-DAC) two to three times daily.
• MK-677 (ibutamoren), orally active ghrelin mimetic. Not technically a peptide (it's a small molecule), but it sits in the same lane. Produces 24-hour GH/IGF-1 elevation, which is the trade-off: convenient daily dosing but no pulse pattern, with notable water retention, increased appetite, and insulin resistance signals at common doses.
• Tesamorelin, stabilized GHRH analog. The only FDA-approved peptide in this group (Egrifta WR, 2010, for HIV-associated lipodystrophy). Two phase III trials showed roughly 15% reduction in visceral adipose tissue over 26 weeks with no change in subcutaneous fat or BMI; 69% of treated patients achieved ≥8% VAT reduction vs. 33% on placebo ^[4]. Long-term cardiovascular safety beyond the trial period is not characterized. Tesamorelin straddles growth and fatLoss in the app, sorted under growth by mechanism, surfaces in fatLoss filters by outcome.

The honest framing on GH secretagogues: they raise IGF-1, often substantially. That's the mechanism by which they do anything useful, and it's also the mechanism that should make you pay attention to what elevated IGF-1 can do over years. Bloodwork matters here.

Cognitive (cognitive)

Nootropic peptides, almost always nasal-route because the nasal mucosa has direct CNS uptake pathways that bypass the blood-brain barrier:

• Semax, heptapeptide derived from ACTH(4-10). Russian-developed, used clinically there for stroke recovery. Reported effects include focus, motivation, BDNF elevation. Almost universally administered as nasal spray; injectable forms exist but bypass the cleaner intranasal-to-CNS route.
• Selank, synthetic analog of tuftsin. Anxiolytic without the sedation/dependency profile of benzodiazepines. Also nasal-route.
• Semax vs. Selank: Semax tilts stimulating/cognitive; Selank tilts calming/anti-anxiety. Frequently stacked at different times of day.

Both sit outside FDA approval entirely in the US and live in the gray-market import lane. Neither was on the original 19-peptide Category 2 list; their compounding pathway has always been narrow.

Specialty (specialty), Sexual, Skin, Sleep & Immune

A deliberately mixed bucket in the app because the compounds share a use pattern (situational, often topical or as-needed) rather than a mechanism. Three sub-uses dominate the peptide cluster here.

Sexual function.

• PT-141 (bremelanotide), melanocortin receptor agonist. FDA-approved as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women. Off-label use in men for erectile and libido issues is widespread. Side effect profile includes nausea, transient hypertension, flushing, and skin darkening with chronic use.

Skin and hair.

• GHK-Cu (copper peptide), endogenous tripeptide bound to copper. Topical applications are well-evidenced for skin barrier, collagen, and wound healing; topical scalp use has limited but suggestive evidence for hair density. Functions as both a cosmetic-grade ingredient and a research peptide depending on the formulation. Most legitimate use is topical, not injected. See the GHK-Cu topical serum guide.

Sleep.

• DSIP (delta sleep-inducing peptide), studied since the 1970s with mixed results. Some sleep-architecture changes in the literature, no clear consensus on practical efficacy. Most users chasing a "sleep peptide" effect get more reliable mileage from sleep hygiene or a low-dose GH secretagogue protocol that lifts deep sleep as a side effect rather than a primary mechanism.

Immune. Less commonly run as standalone protocols; KPV (a fragment of α-MSH) shows up most often as the anti-inflammatory pillar of the KLOW stack rather than as a solo compound.

Fat Loss (fatLoss)

Peptides whose primary outcome is metabolic/visceral-fat-targeted:

• Tesamorelin, see Growth & Recovery. The fat-loss case is the FDA-approved one (visceral adipose tissue reduction in HIV lipodystrophy); it surfaces in this filter for that reason.
• AOD-9604, modified C-terminal fragment of human GH. Marketed for fat loss; clinical efficacy in non-HIV populations is weak in the published literature relative to the marketing.

The overlap with the GLP-1 hub is real and intentional, semaglutide, tirzepatide, and retatrutide are technically peptides and far stronger evidence-base for weight loss than anything in this section. They live in their own pillar at /glp1 because the clinical category, regulatory status, and dosing patterns warrant separate treatment.

Longevity (longevity)

Cross-cutting category, many compounds appear here as a secondary tag rather than a primary home:

• NAD+ (intranasal or injectable), NAD precursor with mitochondrial and DNA-repair claims. Evidence is mostly preclinical and observational; the strongest practical case is for niacin/NMN/NR oral precursors as an adjunct rather than NAD+ itself.
• GHK-Cu when used systemically or in combination with other anti-aging actives.
• Epitalon-class peptides, telomerase claims popularized in longevity communities; underlying clinical evidence is thin and largely sourced from a single Russian research line.

Tag-style use rather than primary-use category. If you're new to peptides, "longevity" should not be the first filter you start in.

The most common mistake is starting with a stack of three to four peptides because that's what was on a forum thread. The defensible alternative:

Start with one peptide tied to one specific outcome you can measure. If it's joint pain after a specific injury, BPC-157 with a clear before/after timeline. If it's sleep and recovery, an Ipamorelin/CJC-1295 (no-DAC) pairing with an IGF-1 baseline and 8-week follow-up. If it's libido, PT-141 on a single-use basis before you commit to anything chronic.

What not to start with:

• Multi-peptide blends. GLOW, KLOW, and Wolverine stacks are convenient, but they make it impossible to attribute effects (or side effects) to a specific compound. Run components individually first, then blend if you've established baselines.
• MK-677 long-term. The 24-hour GH elevation drives water retention and appetite increases that are easy to underestimate. It's not a starter compound for someone who hasn't held a steady weight on baseline diet for at least a few months.
• Anything without a written protocol and a stop date. A peptide protocol with no defined end is a peptide protocol you're going to forget you started. Track it. The OptiPin app was built specifically for this, schedules, sites, vials, and inventory in one place.

The OptiPin medications library covers 200+ peptides and TRT/GLP-1 compounds with typical dosing hints; the free peptide calculator handles vial-to-units math including blend expansion for the common stacks.

This page is not the place to relearn reconstitution math, that's what the peptide calculator is for. The strategic essentials:

• Bacteriostatic water is the standard diluent for most multi-dose peptide vials. Sterile water without preservative is acceptable for single-use only.
• Concentration follows your dose, not the other way around. Pick the BAC water volume that gives you a clean integer number of insulin-syringe units at your target dose. The calculator does this in either direction.
• Lyophilized vs. reconstituted storage. Lyophilized (freeze-dried) vials at refrigeration temperatures are stable for 1–2+ years for most peptides. Once reconstituted, the 28-day rule is a defensible default for refrigerated peptides; some are stable longer, a few are stable shorter. Frozen reconstituted vials can extend stability significantly but introduce freeze-thaw degradation risk if cycled.
• Subcutaneous abdomen or thigh with a 27–31g insulin syringe is the default route for systemic peptides. Local injection (intra-articular, peritendinous) is a separate technique with different risk and should generally be physician-administered.

For the technique itself, drawing, injection angle, site rotation, sharps disposal, see the peptide guide.

Which peptides need cycling, and why

• GH secretagogues need real cycles. Receptor desensitization is the mechanism. Standard cycles run 8–12 weeks on, 4 weeks off, with bloodwork at the boundary so you can see where IGF-1 actually sits.
• MK-677 absolutely needs cycling. The 24-hour GH elevation produces appetite, water retention, and insulin sensitivity changes that are easy to dismiss in week 4 and harder to dismiss in month 6.
• BPC-157 is generally run for a healing window (4–8 weeks at injection-site or systemic doses), then stopped because the indication ended, not because of receptor desensitization. There is no compelling pharmacologic reason for a fixed cycle pattern beyond "stop when the issue is resolved."
• GHK-Cu (topical), Semax, Selank, PT-141, used as-needed or in short courses without formal cycling.

Cycle management is the discipline most peptide users skip. OptiPin's cycle phase tracking handles on/off windows with configurable durations and visual cycle timelines, fires a transition reminder when a cycle window ends, and prompts a bloodwork check at the boundary so the IGF-1 reading actually happens in the off-period when it matters.

The common stacks

Wolverine stack, BPC-157 + TB-500 for soft-tissue and tendon healing. The pairing rationale is mechanistic complementarity: BPC-157 drives angiogenesis and fibroblast activity, TB-500 drives cell migration. Run during a defined healing window with an actual injury or surgery as the indication.

GLOW, typically GHK-Cu + BPC-157 + TB-500. Anti-aging/skin focus when run topically; used by some as injection blend, which is a different risk profile than topical GHK-Cu.

KLOW, KPV (anti-inflammatory) + GHK-Cu + BPC-157 + TB-500. Adds an anti-inflammatory pillar to GLOW.

GH stack, Ipamorelin + CJC-1295 (no-DAC), 2–3× daily. The standard pulse-mimicking GH peptide protocol. Often layered with Tesamorelin for visceral-fat-specific outcomes.

The math for blend dosing is the same shape as single-compound dosing but with a per-component breakdown, the peptide calculator handles this directly with one-tap blend expansion for Wolverine, GLOW, KLOW, and the GH stack. In-app, multi-compound stacks each get their own schedule, dose log, and inventory thread, so a Wolverine-stack run shows you BPC-157 and TB-500 vials independently, remaining volume, doses left, estimated empty date, rather than collapsing into one undifferentiated "stack."

What to actually monitor

The minimum panel for anyone running peptides for more than an 8-week course:

• CBC + comprehensive metabolic panel, baseline and quarterly. Catches kidney, liver, glucose, and red-cell signal.
• IGF-1 and fasting glucose/HbA1c, required if running any GH secretagogue. Elevated IGF-1 is the mechanism by which these peptides do anything; chronically elevated IGF-1 over years is also the signal you want to keep in a safe range.
• Inflammatory markers (hs-CRP), useful for healing-peptide protocols where the goal is exiting an inflammatory state.
• Hormonal panel if stacking with TRT, total/free T, sensitive estradiol, SHBG, prolactin. Some GH peptides shift water/sodium balance enough to perturb the rest of an endocrine protocol.

The OptiPin app pulls lab values directly from Apple Health (or Google Health Connect on Android) as they land, total testosterone, free T, SHBG, IGF-1, hs-CRP, HbA1c, lipid panel, the full set, and plots them against your peptide dose timeline so you can see the markers move in response to actual cycle boundaries. The AI summary reads the full record (doses, daily symptoms, weight, sleep, labs) and surfaces the patterns: which compound correlated with the IGF-1 jump, when the inflammation marker dropped, where the protocol added signal vs. noise. Most users find this faster than reviewing individual charts.

Sourcing risk and quality control

This is the part most peptide content avoids talking about. The same compound can be 99% pure in one vial and 70% pure in another from a different vendor, and you can't tell by looking. The actionable rules:

• Buy from vendors that publish third-party HPLC purity testing with batch-matched certificates of analysis. "Research grade" without a CoA is a marketing label, not a quality claim.
• Be skeptical of unusually cheap pricing. Peptide synthesis has a real cost floor. Substantially-below-market pricing usually means underdosed or impure product.
• Reconstitute and discard on a calendar, not when the vial empties. A 6-month-old "still has product in it" vial that's been at fridge temp through transit is not the same product you started with. (OptiPin's vial inventory tracks reconstitution date per vial, fires a discard alert at the 28-day mark by default, configurable per compound, and warns when a vial is approaching empty so you don't run out mid-cycle.)
• The 2023 reclassification matters here. 19 peptides commonly compounded under 503A, including BPC-157, CJC-1295, ipamorelin, GHK-Cu, semax, and selank, were placed in Category 2 ("significant safety risk for compounding"), which constrained licensed compounding pharmacies from filling them. The market response was a surge in gray-market and "research-only" sourcing, which raised QC stakes rather than lowered them. The 2026 reconsideration may reverse this for ~14 of the 19, but as of mid-2026 the formal rule has not changed.

Where the FDA peptide framework actually stands (2026)

The current state is in active flux. The history compresses to:

• 2023: FDA placed 19 peptides into Category 2 under the section 503A interim policy, significant safety risk for compounding under that pathway. Effect: licensed 503A pharmacies stopped filling them; market shifted to gray-market and research-only sourcing.
• January 7, 2025: FDA finalized the 503A interim policy guidance, retaining the Category 1 / Category 2 framework and announcing that no new substances would be added to either category for 503B (outsourcing facility) compounding going forward ^[5]. This is a procedural change, not a peptide-list change.
• February 2026: HHS Secretary RFK Jr. publicly stated that ~14 of the 19 Category 2 peptides should be returned to Category 1. The FDA scheduled an advisory committee for July 23–24, 2026 to evaluate seven peptides including BPC-157, with a second panel before February 2027 covering five more.
• As of mid-2026: No formal rule change. The Federal Register has not published a revised list, and the legal compounding status of the 19 peptides has not actually moved. What changed is the political signal and the expected direction.

What this means for anyone running peptides today:

• The licensed compounding channel for the affected peptides is still effectively closed in the US, despite the announcements.
• A reversal is plausible but not guaranteed, the advisory committee can recommend against reclassification on safety grounds, and FDA is not bound by either RFK's preference or the committee's recommendation.
• If access does loosen, the smart sourcing move will be migrating from gray-market vendors back to licensed compounding pharmacies for QC and legal reasons. The compounds themselves do not change; the supply chain does.
• Plan as if the current state holds. Anyone choosing a peptide today on the assumption "it'll be legal again by year-end" is making a regulatory bet, not a clinical decision.

See the country-by-country peptides access guide for specifics outside the US. The Canada, EU, and Australia frameworks are unaffected by US Category 1/2 placement and have their own access patterns.

Not every peptide needs an injection. Two routes deserve their own framing:

Nasal-route peptides

The nasal mucosa is permeable to small peptides and has direct CNS uptake pathways that bypass the blood-brain barrier, which is why Semax and Selank are essentially always administered intranasally. For these compounds, the nasal route is the standard, not an alternative.

For peptides that have systemic targets (BPC-157, for example), nasal administration is partial-bioavailability alternative to injection: the absorption window is real but variable, and the dose-response is harder to characterize than with subcutaneous injection. The framing: nasal makes sense for compounds with nasal-route evidence (Semax, Selank, intranasal NAD+, some forms of intranasal BPC-157 for upper-respiratory or CNS indications) and is a compromise for compounds whose primary evidence base is parenteral.

GLP-1 agonists (semaglutide, tirzepatide) do not work nasally. The molecular weight and structure make nasal absorption negligible. Marketing claims to the contrary should be treated as marketing.

Topical peptides

GHK-Cu is the primary topical peptide with reasonable evidence, copper-bound tripeptide formulations for skin barrier, collagen, and wound healing have been studied in cosmetic and dermatology contexts for decades. Topical application has effectively zero systemic exposure, which makes it the lowest-risk peptide protocol available. The topical GHK-Cu guide covers concentration, application protocol, and stacking with other actives.

Other "topical peptides" (matrixyl, palmitoyl variants) are largely cosmetic-industry compounds with skin-barrier and collagen claims that range from well-supported (the matrikines) to marketing-driven.